C.R. Bard Receives Average Rating of “Hold” from Analysts (NYSE:BCR)
Shares of C.R. Bard (NYSE:BCR) have received an average recommendation of “Hold” from the nineteen brokerages that are presently covering the company, Analyst Ratings.Net reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $133.80.
C.R. Bard (NYSE:BCR) opened at 128.40 on Friday. C.R. Bard has a 52-week low of $97.14 and a 52-week high of $141.02. The stock has a 50-day moving average of $132.4 and a 200-day moving average of $126.. The company has a market cap of $10.001 billion and a price-to-earnings ratio of 15.30.
C.R. Bard (NYSE:BCR) last released its earnings data on Thursday, January 30th. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.41 by $0.01. The company had revenue of $791.30 million for the quarter, compared to the consensus estimate of $782.28 million. Analysts expect that C.R. Bard will post $8.26 EPS for the current fiscal year.
BCR has been the subject of a number of recent research reports. Analysts at Barclays raised their price target on shares of C.R. Bard from $140.00 to $150.00 in a research note to investors on Thursday, January 9th. They now have an “overweight” rating on the stock. Separately, analysts at Atlantic Securities upgraded shares of C.R. Bard from a “neutral” rating to an “overweight” rating in a research note to investors on Wednesday, January 8th. They now have a $148.00 price target on the stock, up previously from $118.00. Finally, analysts at JPMorgan Chase & Co. downgraded shares of C.R. Bard from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, January 6th. They now have a $142.00 price target on the stock. They noted that the move was a valuation call.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.